Hanmi’s 3-sbustance combination drug containing Amosartan & rosuvastatin represented at EHS
2 case results of clinical trial for ‘Amosartan,’ a combination drug developed by Hanmi Pharm, were announced at the European Society of Hypertension(ESH).
Hanmi Pharm announced on the 20th that it presented a Phase 3 clinical trial result of the 3-substance combination drug containing the Amosa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
